Senhwa Biosciences, Inc. (TPEx: 6492) announced it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE